I D Cockshott
Overview
Explore the profile of I D Cockshott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cockshott I
Clin Pharmacokinet
. 2000 Aug;
39(1):27-48.
PMID: 10926349
Goserelin is a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH). For experimental purposes it has been administered subcutaneously as an aqueous solution, but for therapeutic use it is formulated...
2.
Ickx B, Cockshott I, Barvais L, Byttebier G, De Pauw L, Vandesteene A, et al.
Br J Anaesth
. 1999 Apr;
81(6):854-60.
PMID: 10211008
We have investigated the pharmacokinetics and pharmacodynamics of propofol in 11 patients with end-stage renal disease (ESRD) compared with nine healthy patients during and after a manually controlled three-stage infusion...
3.
Tyrrell C, Denis L, Newling D, Soloway M, Channer K, Cockshott I
Eur Urol
. 1998 Feb;
33(1):39-53.
PMID: 9471040
Objectives: To evaluate the efficacy, tolerability, endocrinological effects and the pharmacokinetics of Casodex, when given as monotherapy during daily dosing of 10-200 mg to patients with advanced prostate cancer. Methods:...
4.
Cockshott I, Oliver S, Young J, Cooper K, DC Jones
Biopharm Drug Dispos
. 1997 Aug;
18(6):499-507.
PMID: 9312310
'Casodex' (bicalutamide) is an orally active, non-steroidal, pure antiandrogen; it is a racemate with antiandrogenic activity residing predominantly in the (R)-enantiomer. Healthy male volunteers (n = 15) were administered single...
5.
Blackledge G, Cockshott I, Furr B
Eur Urol
. 1997 Jan;
31 Suppl 2:30-9.
PMID: 9074908
Casodex (bicalutamide, Zeneca Ltd), has been developed for prostate cancer therapy. Its preclinical, pharmacokinetic, pharmacodynamic, clinical efficacy and tolerability data are described. Casodex is a potent and specific non-steroidal antiandrogen....
6.
McKillop D, Simons P, Cockshott I, Hill S, Harding J, Cooper K, et al.
Xenobiotica
. 1995 Jun;
25(6):623-33.
PMID: 7483662
1. Casodex, a non-steroidal antiandrogen, is a racemic mixture of R-Casodex, the pharmacologically active (-)-enantiomer, and S-Casodex, the inactive (+)-enantiomer. Single oral doses of pseudo-racemic 14C-Casodex (10 mg/kg), prepared from...
7.
McKillop D, Boyle G, Cockshott I, Jones D, Phillips P, YATES R
Xenobiotica
. 1993 Nov;
23(11):1241-53.
PMID: 8310708
1. Five healthy male volunteers received a single oral dose (50 mg; 42 microCi) of 14C-Casodex, a racemic compound, which has its antiandrogen activity predominantly in R-Casodex, the (-)-enantiomer, with...
8.
Cockshott I, Sotaniemi E, Cooper K, Jones D
Br J Clin Pharmacol
. 1993 Oct;
36(4):339-43.
PMID: 12959312
1. Casodex is a novel non-steroidal antiandrogen being developed for the treatment of prostatic cancer. The antiandrogenic activity is predominantly in the R(-) enantiomer with little, if any, activity in...
9.
Simons P, Cockshott I, Glen J, Gordon E, Knott S, Ruane R
Xenobiotica
. 1992 Nov;
22(11):1267-73.
PMID: 1492419
1. Propofol glucuronide (PG) is the major human metabolite of the i.v. anaesthetic propofol, 2,6-diisopropylphenol. 2. Bolus i.v. doses of 14C-PG (1 mg/kg) to rat and dog were eliminated in...
10.
Cockshott I, Haywood J
Biopharm Drug Dispos
. 1992 Aug;
13(6):461-80.
PMID: 1391682
SIPHAR and MKMODEL in their extended least squares modes have been compared when fitting a triexponential declining function to simulated data. The data were simulated on SAS incorporating normally distributed...